vs

Side-by-side financial comparison of IMAX CORP (IMAX) and Immunocore Holdings plc (IMCR). Click either name above to swap in a different company.

IMAX CORP is the larger business by last-quarter revenue ($125.2M vs $104.5M, roughly 1.2× Immunocore Holdings plc). On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs 24.3%). IMAX CORP produced more free cash flow last quarter ($28.0M vs $-35.5M). Over the past eight quarters, IMAX CORP's revenue compounded faster (25.8% CAGR vs 21.7%).

IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.

Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.

IMAX vs IMCR — Head-to-Head

Bigger by revenue
IMAX
IMAX
1.2× larger
IMAX
$125.2M
$104.5M
IMCR
Growing faster (revenue YoY)
IMAX
IMAX
+10.8% gap
IMAX
35.1%
24.3%
IMCR
More free cash flow
IMAX
IMAX
$63.5M more FCF
IMAX
$28.0M
$-35.5M
IMCR
Faster 2-yr revenue CAGR
IMAX
IMAX
Annualised
IMAX
25.8%
21.7%
IMCR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IMAX
IMAX
IMCR
IMCR
Revenue
$125.2M
$104.5M
Net Profit
$637.0K
Gross Margin
57.6%
97.4%
Operating Margin
19.3%
-18.8%
Net Margin
0.5%
Revenue YoY
35.1%
24.3%
Net Profit YoY
-88.0%
EPS (diluted)
$0.02
$-0.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMAX
IMAX
IMCR
IMCR
Q4 25
$125.2M
$104.5M
Q3 25
$106.7M
$103.7M
Q2 25
$91.7M
$98.0M
Q1 25
$86.7M
$93.9M
Q4 24
$92.7M
$84.1M
Q3 24
$91.5M
$80.2M
Q2 24
$89.0M
$75.4M
Q1 24
$79.1M
$70.5M
Net Profit
IMAX
IMAX
IMCR
IMCR
Q4 25
$637.0K
Q3 25
$20.7M
$-177.0K
Q2 25
$11.3M
$-10.3M
Q1 25
$2.3M
$5.0M
Q4 24
$5.3M
Q3 24
$13.9M
$8.7M
Q2 24
$3.6M
$-11.6M
Q1 24
$3.3M
$-24.4M
Gross Margin
IMAX
IMAX
IMCR
IMCR
Q4 25
57.6%
97.4%
Q3 25
63.1%
99.5%
Q2 25
58.5%
98.9%
Q1 25
61.4%
99.1%
Q4 24
52.2%
99.6%
Q3 24
55.8%
99.4%
Q2 24
49.4%
97.7%
Q1 24
59.3%
99.7%
Operating Margin
IMAX
IMAX
IMCR
IMCR
Q4 25
19.3%
-18.8%
Q3 25
27.2%
-6.9%
Q2 25
15.6%
-15.2%
Q1 25
19.3%
-3.9%
Q4 24
10.3%
-23.1%
Q3 24
21.2%
-10.6%
Q2 24
3.2%
-21.2%
Q1 24
15.3%
-37.6%
Net Margin
IMAX
IMAX
IMCR
IMCR
Q4 25
0.5%
Q3 25
19.4%
-0.2%
Q2 25
12.3%
-10.5%
Q1 25
2.7%
5.4%
Q4 24
5.7%
Q3 24
15.2%
10.9%
Q2 24
4.0%
-15.4%
Q1 24
4.1%
-34.7%
EPS (diluted)
IMAX
IMAX
IMCR
IMCR
Q4 25
$0.02
$-0.61
Q3 25
$0.37
$0.00
Q2 25
$0.20
$-0.20
Q1 25
$0.04
$0.10
Q4 24
$0.09
$-0.47
Q3 24
$0.26
$0.17
Q2 24
$0.07
$-0.23
Q1 24
$0.06
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMAX
IMAX
IMCR
IMCR
Cash + ST InvestmentsLiquidity on hand
$151.2M
$864.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$337.9M
$381.0M
Total Assets
$894.0M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMAX
IMAX
IMCR
IMCR
Q4 25
$151.2M
$864.2M
Q3 25
$143.1M
$892.4M
Q2 25
$109.3M
$882.8M
Q1 25
$97.1M
$837.0M
Q4 24
$100.6M
$820.4M
Q3 24
$104.5M
$901.3M
Q2 24
$91.6M
$859.6M
Q1 24
$81.0M
$832.8M
Total Debt
IMAX
IMAX
IMCR
IMCR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$438.7M
Q2 24
$452.5M
Q1 24
$452.5M
Stockholders' Equity
IMAX
IMAX
IMCR
IMCR
Q4 25
$337.9M
$381.0M
Q3 25
$349.5M
$396.6M
Q2 25
$320.4M
$388.5M
Q1 25
$299.5M
$378.5M
Q4 24
$299.5M
$360.7M
Q3 24
$289.4M
$377.8M
Q2 24
$267.2M
$359.1M
Q1 24
$258.8M
$359.5M
Total Assets
IMAX
IMAX
IMCR
IMCR
Q4 25
$894.0M
$1.1B
Q3 25
$889.6M
$1.1B
Q2 25
$868.6M
$1.1B
Q1 25
$848.3M
$1.0B
Q4 24
$830.4M
$1.0B
Q3 24
$847.6M
$1.1B
Q2 24
$827.4M
$1.0B
Q1 24
$824.1M
$994.0M
Debt / Equity
IMAX
IMAX
IMCR
IMCR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
1.16×
Q2 24
1.26×
Q1 24
1.26×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMAX
IMAX
IMCR
IMCR
Operating Cash FlowLast quarter
$29.4M
$-32.7M
Free Cash FlowOCF − Capex
$28.0M
$-35.5M
FCF MarginFCF / Revenue
22.3%
-34.0%
Capex IntensityCapex / Revenue
1.1%
2.8%
Cash ConversionOCF / Net Profit
46.11×
TTM Free Cash FlowTrailing 4 quarters
$118.9M
$-15.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMAX
IMAX
IMCR
IMCR
Q4 25
$29.4M
$-32.7M
Q3 25
$67.5M
$-4.5M
Q2 25
$23.2M
$26.0M
Q1 25
$7.0M
$435.0K
Q4 24
$11.5M
$-14.0M
Q3 24
$35.3M
$21.1M
Q2 24
$35.0M
$23.5M
Q1 24
$-11.0M
$-4.6M
Free Cash Flow
IMAX
IMAX
IMCR
IMCR
Q4 25
$28.0M
$-35.5M
Q3 25
$64.8M
$-5.2M
Q2 25
$20.9M
$25.6M
Q1 25
$5.3M
$137.0K
Q4 24
$6.9M
$-17.5M
Q3 24
$34.2M
$20.3M
Q2 24
$33.5M
$23.1M
Q1 24
$-12.1M
$-5.0M
FCF Margin
IMAX
IMAX
IMCR
IMCR
Q4 25
22.3%
-34.0%
Q3 25
60.7%
-5.0%
Q2 25
22.8%
26.1%
Q1 25
6.1%
0.1%
Q4 24
7.4%
-20.9%
Q3 24
37.3%
25.3%
Q2 24
37.6%
30.7%
Q1 24
-15.3%
-7.1%
Capex Intensity
IMAX
IMAX
IMCR
IMCR
Q4 25
1.1%
2.8%
Q3 25
2.6%
0.7%
Q2 25
2.6%
0.4%
Q1 25
1.9%
0.3%
Q4 24
5.0%
4.3%
Q3 24
1.2%
1.0%
Q2 24
1.8%
0.4%
Q1 24
1.4%
0.6%
Cash Conversion
IMAX
IMAX
IMCR
IMCR
Q4 25
46.11×
Q3 25
3.27×
Q2 25
2.06×
Q1 25
2.99×
0.09×
Q4 24
2.16×
Q3 24
2.54×
2.42×
Q2 24
9.78×
Q1 24
-3.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMAX
IMAX

Technology Sales$46.6M37%
Image Enhancement And Maintenance Services$38.1M30%
Joint Revenue Sharing Arrangement$20.4M16%
Maintenance$16.3M13%
Finance Income$2.8M2%
Other Content Solutions$1.6M1%

IMCR
IMCR

Segment breakdown not available.

Related Comparisons